Injectable vitamin d3 dose and schedule for injection
Reading File
Finding Sources
Searching PubMed
"vitamin D3" AND injection AND cholecalciferol
Searching the Web
injectable vitamin D3 cholecalciferol dose schedule intramuscular injection deficiency treatment
Finding Sources
Here is a full clinical reference on Injectable Vitamin D3 (Cholecalciferol) - Dose and Schedule:
Injectable Vitamin D3 (Cholecalciferol) - Dose and Schedule
Formulation
- Available as a sterile, oil-based (e.g., grapeseed oil) solution for deep intramuscular (IM) injection
- Common concentrations: 100,000 IU/mL (e.g., Vitamin D3 B.O.N.)
- Route: Deep IM (gluteal muscle); NOT intravenous
Indications for Injectable Route
Injectable vitamin D3 is preferred over oral when:
- Malabsorption syndromes (Crohn's, celiac, short gut)
- Post-bariatric surgery
- Poor oral compliance or adherence
- Severe/symptomatic deficiency requiring rapid correction
- Patients who cannot take oral medications
Dosing Schedules
1. Stoss (Loading) Therapy - Severe Deficiency (25-OHD < 10 ng/mL)
| Regimen | Dose | Frequency | Total |
|---|---|---|---|
| Single megadose | 600,000 IU IM | Once (annual) | 600,000 IU |
| Split loading | 300,000 IU IM | Once, repeat in 4 weeks if needed | 300,000-600,000 IU |
| Monthly loading | 100,000 IU IM | Every 4 weeks x 2-3 doses | 200,000-300,000 IU |
A single annual IM injection of 600,000 IU has been shown effective and safe in adults with vitamin D deficiency, with serum 25-OHD rising significantly at 4 and 12 months (Diamond et al., 2005).
2. Moderate Deficiency (25-OHD 10-20 ng/mL)
- 300,000 IU IM once - followed by oral maintenance
- OR 100,000 IU IM monthly x 3 months - then reassess
3. Maintenance / Prevention
- 100,000-200,000 IU IM every 3 months (quarterly)
- OR 200,000 IU IM every 6 months
- Annual: 600,000 IU IM once yearly
4. Special Populations
| Population | Regimen |
|---|---|
| Elderly (frail, nursing home) | 200,000 IU IM at baseline, then 3-monthly follow-up |
| Malabsorption | 300,000 IU IM monthly x 3 months, then twice yearly |
| Post-bariatric | 300,000 IU IM every 2-3 months |
| Severe deficiency + hyperparathyroidism | 300,000-600,000 IU IM, reassess at 3 months |
Monitoring
- Check serum 25-OHD at baseline and 8-12 weeks after loading
- Also monitor: serum calcium, creatinine, and PTH
- Urine calcium/creatinine ratio if high doses used
- Target 25-OHD: 30-50 ng/mL (75-125 nmol/L)
Oral Maintenance After Loading
After IM loading, transition to oral maintenance:
- 1,500-2,000 IU/day (Endocrine Society recommendation)
- OR 50,000 IU/month oral cholecalciferol
Pharmacokinetics of IM vs. Oral
- IM injection creates a tissue depot in muscle, releasing D3 slowly over weeks to months - this is the key advantage over oral dosing
- Peak serum 25-OHD typically reached at 2-4 weeks post-injection
- Duration of effect: A single 300,000 IU IM dose maintains adequate levels for approximately 3 months; 600,000 IU may sustain for up to 12 months
Contraindications
- Hypercalcemia
- Hypervitaminosis D (25-OHD > 150 ng/mL)
- Idiopathic infantile hypercalcemia
- Hypersensitivity to cholecalciferol or the oil vehicle
- Conditions with risk of hypercalcemia: sarcoidosis, primary hyperparathyroidism (use with caution)
Key Safety Notes
- Toxicity is rare but possible with excessive dosing (serum 25-OHD > 150 ng/mL)
- Risk of hypercalciuria with megadose therapy - monitor urine calcium
- Injection site reactions possible with oil-based formulations
- Recent meta-analysis (2025) found calcifediol raises 25-OHD more rapidly than cholecalciferol, though both are effective
Summary Table - Common IM Regimens
| Indication | Dose | Schedule |
|---|---|---|
| Severe deficiency | 600,000 IU | Single annual injection |
| Severe deficiency | 300,000 IU | Once, repeat x1 at 4-8 weeks |
| Moderate deficiency | 100,000 IU | Monthly x 3 months |
| Maintenance (quarterly) | 100,000-200,000 IU | Every 3 months |
| Maintenance (biannual) | 300,000 IU | Every 6 months |
| Maintenance (annual) | 600,000 IU | Once yearly |
Note: These are adult dosing guidelines. Pediatric dosing differs significantly. Always individualize based on baseline 25-OHD level, body weight, malabsorption severity, season, and co-morbidities. Confirm with current local guidelines.
This is a shared conversation. Sign in to Orris to start your own chat.